Clinical Trials Logo

Myelogenous Leukemia, Acute clinical trials

View clinical trials related to Myelogenous Leukemia, Acute.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00907517 Terminated - Clinical trials for Leukemia, Lymphocytic, Acute

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

Start date: July 29, 2009
Phase: Phase 1
Study type: Interventional

This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias. Participants in the Dose-Escalation Part will be enrolled in cohorts that will receive sequentially higher doses of MK-8776 in combination with standard doses of cytarabine. Only one combination treatment cycle of approximately 4 to 6 weeks is anticipated, but participants may receive additional cycles if clinically indicated after discussion between the Investigator and the Sponsor. The recommended combination doses for a Phase 2 trial (RP2D) will be determined based on safety and biological activity. Up to 10 to 15 additional participants will be studied at the combination RP2D.

NCT ID: NCT00374296 Terminated - Clinical trials for Myelodysplastic Syndromes

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Start date: September 2006
Phase: Phase 2
Study type: Interventional

In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.